Halper Sadeh LLC investigates Steelcase, LAVA Therapeutics, Enzo Biochem for potential securities law breaches.

Halper Sadeh LLC is investigating Steelcase Inc.'s sale of HNI Corporation for potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders. The law firm is also investigating LAVA Therapeutics N.V.'s sale to XOMA Royalty Corporation and Enzo Biochem, Inc.'s sale to Battery Ventures. Shareholders can learn more about their rights and options by clicking on the provided links.

Halper Sadeh LLC, an investor rights law firm, has initiated investigations into three significant corporate sales, alleging potential violations of federal securities laws and breaches of fiduciary duties to shareholders. The firm is examining the transactions involving Steelcase Inc. (NYSE: SCS), LAVA Therapeutics N.V. (NASDAQ: LVTX), and Enzo Biochem, Inc. (OTCMKTS: ENZB).

Steelcase Inc. (NYSE: SCS)

Halper Sadeh LLC is investigating whether the sale of Steelcase Inc. to HNI Corporation for $7.20 in cash and 0.2192 shares of HNI common stock per share of Steelcase is fair to shareholders. The investigation concerns whether Steelcase and its board of directors failed to obtain the best possible consideration for shareholders, determine if HNI is underpaying for Steelcase, and disclose all material information necessary for shareholders to adequately assess and value the merger consideration [1].

LAVA Therapeutics N.V. (NASDAQ: LVTX)

The law firm is also investigating the sale of LAVA Therapeutics N.V. to XOMA Royalty Corporation. Under the terms of the proposed transaction, XOMA Royalty will acquire LAVA for between $1.16 and $1.24 per share in cash, plus a non-transferable contingent value right (CVR) representing 75% of net proceeds from LAVA’s partnered assets and any out-licensing or sale of unpartnered programs [2]. Halper Sadeh contends that the sale may be unfair to LVTX shareholders, claiming potential violations of federal securities laws and breaches of fiduciary duties by LVTX and its board of directors.

Enzo Biochem, Inc. (OTCMKTS: ENZB)

Additionally, Halper Sadeh LLC is investigating the sale of Enzo Biochem, Inc. to Battery Ventures for $0.70 per share in cash. The firm is examining whether this sale is fair to Enzo shareholders and if the board of directors fulfilled its fiduciary duties [3].

Shareholders are encouraged to contact Halper Sadeh LLC to learn more about their legal rights and options. The law firm handles such actions on a contingent fee basis, meaning shareholders would not be responsible for out-of-pocket payment of legal fees or expenses.

References

[1] https://www.morningstar.com/news/business-wire/20250804851848/scs-stock-alert-halper-sadeh-llc-is-investigating-whether-the-sale-of-steelcase-inc-is-fair-to-shareholders
[2] https://www.ainvest.com/news/investigation-fairness-lava-therapeutics-sale-xoma-royalty-corporation-2508/
[3] https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-scs-lvtx-enzb-on-behalf-of-shareholders-302524965.html